Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
TenSixteen Bio launched Thursday with a $40 million Series A financing round funded by Foresite Capital and GV, formerly Google Ventures.
The resubmission follows a Type B pre-BLA resubmission meeting with the US Food and Drug Administration (FDA).
Clinical trial news definitely picked up this final week of January. Here’s a look.
A new report showed the increased funding in 2021 mirrors national data that show accelerated financing in support of new therapies for multiple diseases, driven by COVID-19 concerns.
Researchers are expressing concern about a subvariant of Omicron dubbed BA.2 that appears to be tearing through Denmark. For that and more COVID-19 news, continue reading.
Oxford BioMedica and Homology Medicines have formed a symbiotic partnership to launch a full scope AAV manufacturing and innovation business.
Taysha said the data for TSHA-101 is the “first-ever to support the bicistronic vector approach in humans delivering both HEXA and HEXB genes in the endogenous ratio.”
Biogen is selling its nearly 50% stake in Samsung Bioepis for $2.3 billion. The move will provide Biogen with additional capital while preparing to cut additional costs through a rumored employee layoff.
The FDA had accepted the sBLA in September 2021 under priority review status.
Moderna invested heavily in mRNA technology to manufacture some 900 million doses of the COVID-19 vaccine. Now, the company has created an mRNA-based vaccine to prevent HIV.
The company initiated the use of splenic nerve simulation last month as part of a small clinical trial at the NHS Greater Glasgow & Clyde Health Board in Scotland.
Alzamend Neuro is looking to commence a Phase II multiple ascending dose study of lead compound, AL001, in Alzheimer’s disease during the second quarter of this year.
PRESS RELEASES
Pharmaceutical service provider receives prestigious management award for the seventh year in a row · Family-owned company once again excels in all four key business areas · Site development and digitalization as strategic investment priorities · Focus on new sources for skilled workers and on lifelong learning
The upgraded platform offers a searchable database of over 300 risk-assessed HCPs, automated research scanning, and new flexible pricing options for mid-size drug developers.
New preprint by Jianghui Xiong, PhD, and the DeepoMe team introduces SteeraMed, a steerable biomedical world model for N-of-1 intervention reasoning across chronic diseases and aging